Naitoh M, Suzuki H, Murakami M, Matsumoto A, Ichihara A, Nakamoto H, Yamamura Y, Saruta T
Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Am J Physiol. 1993 Oct;265(4 Pt 2):R934-42. doi: 10.1152/ajpregu.1993.265.4.R934.
In conscious dogs, 36-h water deprivation induced a significant increase in renal blood flow (RBF) with elevation of the plasma arginine vasopressin (AVP) concentration to 9.6 +/- 1.8 pg/ml. To simulate such a condition, a mild elevation of plasma AVP was produced by infusing AVP intravenously at a dose of 0.1 ng.kg-1.min-1 for 20 min. The plasma AVP concentration then increased to 6.8 +/- 0.7 pg/ml. This dose of AVP increased the RBF by 21.7 +/- 2.6% and decreased the renal vascular resistance by 18.1 +/- 2.3% without significant changes in mean arterial pressure, cardiac output, or heart rate. The mechanism of this renal vasodilatory action was examined using newly developed, orally effective, selective AVP antagonists OPC-21268 (a V1-receptor antagonist) and OPC-31260 (a V2-receptor antagonist). In 36-h water-deprived dogs, V2-receptor blockade with OPC-31260 significantly decreased the RBF by 20.5 +/- 2.6% without significant changes in cardiac output. The exogenous AVP-induced renal vasodilatory response tended to be augmented when V1 receptors were blocked by pretreatment with OPC-21268, but the change did not achieve statistical significance. On the other hand, V2-receptor blockade by either pretreatment with OPC-31260 or simultaneous infusion of OPC-31260 inhibited this vasodilatory response. Furthermore, intravenous infusion of 1-desamino-8-D-arginine vasopressin (DDAVP) at a dose of 0.3 ng.kg-1 x min-1 for 20 min significantly increased the RBF by 36.5 +/- 1.7%, and this DDAVP-induced renal vasodilation was inhibited by simultaneous infusion of V2-receptor antagonist.(ABSTRACT TRUNCATED AT 250 WORDS)
在清醒犬中,36小时禁水使肾血流量(RBF)显著增加,同时血浆精氨酸血管加压素(AVP)浓度升高至9.6±1.8 pg/ml。为模拟这种情况,通过以0.1 ng·kg⁻¹·min⁻¹的剂量静脉输注AVP 20分钟,使血浆AVP轻度升高。此时血浆AVP浓度升至6.8±0.7 pg/ml。该剂量的AVP使RBF增加21.7±2.6%,肾血管阻力降低18.1±2.3%,而平均动脉压、心输出量或心率无显著变化。使用新开发的口服有效的选择性AVP拮抗剂OPC - 21268(V1受体拮抗剂)和OPC - 31260(V2受体拮抗剂)研究了这种肾血管舒张作用的机制。在36小时禁水的犬中,用OPC - 31260阻断V2受体可使RBF显著降低20.5±2.6%,而心输出量无显著变化。当用OPC - 21268预处理阻断V1受体时,外源性AVP诱导的肾血管舒张反应有增强趋势,但变化未达到统计学显著性。另一方面,用OPC - 31260预处理或同时输注OPC - 31260阻断V2受体可抑制这种血管舒张反应。此外,以0.3 ng·kg⁻¹·min⁻¹的剂量静脉输注1 - 去氨基 - 8 - D - 精氨酸血管加压素(DDAVP)20分钟可使RBF显著增加36.5±1.7%,同时输注V2受体拮抗剂可抑制DDAVP诱导的肾血管舒张。(摘要截短于250字)